OOIR: Observatory of International Research

Papers

(The H4-Index of mAbs is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	299
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	236
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	139
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	116
In silico prediction of post-translational modifications in therapeutic antibodies	108
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	92
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on Klebsiella pneumoniae	79
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	75
Correction	73
Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries	66
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	66
An antibody developability triaging pipeline exploiting protein language models	63
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	60
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	59
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	53
Correction	48
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	45
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	43
Correction	40
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	40
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	40
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	39
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	38
Predicting antibody binders and generating synthetic antibodies using deep learning	37
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	36

Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	36
The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	35
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	35
Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability	34
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	33
Impact of IgG subclass on monoclonal antibody developability	32
Structural and functional characterization of a monoclonal antibody blocking TIGIT	31